{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:05:27Z","timestamp":1787799927808,"version":"build-2784847793"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/hr.2017.65","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T06:00:26Z","timestamp":1499320826000},"page":"903-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?"],"prefix":"10.1038","volume":"40","author":[{"given":"Ali","family":"Nehme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Zibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"BFhr201765_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/WCO.0b013e32835c4f54","volume":"26","author":"DT Lackland","year":"2013","unstructured":"Lackland DT . Hypertension: joint national committee on detection, evaluation, and treatment of high blood pressure guidelines. Curr Opin Neurol 2013; 26: 8\u201312.","journal-title":"Curr Opin Neurol"},{"key":"BFhr201765_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.cjca.2012.10.007","volume":"29","author":"RS McKelvie","year":"2013","unstructured":"McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, Estrella-Holder E, Giannetti N, Grzeslo A, Harkness K, Howlett JG, Kouz S, Leblanc K, Mann E, Nigam A, O\u2019Meara E, Rajda M, Steinhart B, Swiggum E, Le VV, Zieroth S, Arnold JMO, Ashton T, D\u2019Astous M, Dorian P, Haddad H, Isaac DL, Leblanc M-H, Liu P, Ross HJ, Sussex B . The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol 2013; 29: 168\u2013181.","journal-title":"Can J Cardiol"},{"key":"BFhr201765_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/01.HYP.35.3.780","volume":"35","author":"J Bohlender","year":"2000","unstructured":"Bohlender J, M\u00e9nard J, Ganten D, Luft FC . Angiotensinogen concentrations and renin clearance implications for blood pressure regulation. Hypertension 2000; 35: 780\u2013786.","journal-title":"Hypertension"},{"key":"BFhr201765_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00109-008-0344-0","volume":"86","author":"X Jeunemaitre","year":"2008","unstructured":"Jeunemaitre X . Genetics of the human renin angiotensin system. J Mol Med (Berl) 2008; 86: 637\u2013641.","journal-title":"J Mol Med (Berl)"},{"key":"BFhr201765_CR5","first-page":"691","volume":"45","author":"JD Swales","year":"1973","unstructured":"Swales JD, Thurston H . Generation of angiotensin II at peripheral vascular level: studies using angiotensin II antisera. Clin Sci Mol Med 1973; 45: 691\u2013700.","journal-title":"Clin Sci Mol Med"},{"key":"BFhr201765_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"M Paul","year":"2006","unstructured":"Paul M, Mehr AP, Kreutz R . Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747\u2013803.","journal-title":"Physiol Rev"},{"key":"BFhr201765_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1590\/S0100-879X2011007500093","volume":"44","author":"C Becari","year":"2011","unstructured":"Becari C, Oliveira EB, Salgado MCO . Alternative pathways for angiotensin II generation in the cardiovascular system. Braz J Med Biol Res 2011; 44: 914\u2013919.","journal-title":"Braz J Med Biol Res"},{"key":"BFhr201765_CR8","doi-asserted-by":"publisher","first-page":"F749","DOI":"10.1152\/ajprenal.00383.2009","volume":"300","author":"MC Prieto","year":"2011","unstructured":"Prieto MC, Gonz\u00e1lez-Villalobos RA, Botros FT, Martin VL, Pag\u00e1n J, Satou R, Lara LS, Feng Y, Fernandes FB, Kobori H, Casarini DE, Navar LG . Reciprocal changes in renal ACE\/ANG II and ACE2\/ANG 1\u20137 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2011; 300: F749\u2013F755.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFhr201765_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1590\/S0100-879X2011007500093","volume":"44","author":"C Becari","year":"2011","unstructured":"Becari C, Oliveira EB, Salgado MCO . Alternative pathways for angiotensin II generation in the cardiovascular system. Braz J Med Biol Res 2011; 44: 914\u2013919.","journal-title":"Braz J Med Biol Res"},{"key":"BFhr201765_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1172\/JCI17845","volume":"112","author":"H Masuzaki","year":"2003","unstructured":"Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MGF, Fleming S, Mullins JJ, Seckl JR, Flier JS . Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112: 83\u201390.","journal-title":"J Clin Invest"},{"key":"BFhr201765_CR11","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00109-014-1193-7","volume":"92","author":"H Ayari","year":"2014","unstructured":"Ayari H, Legedz L, Cerutti C, Lantelme P, Feugier P, Gustin M-P, Lohez O, Nehme A, Li JY, Gharbi-Chihi J, Bricca G . Mutual amplification of corticosteroids and angiotensin systems in human vascular smooth muscle cells and carotid atheroma. J Mol Med (Berl) 2014; 92: 1201\u20131208.","journal-title":"J Mol Med (Berl)"},{"key":"BFhr201765_CR12","unstructured":"National Institute for Health and Care Excellence (NICE). Renin-angiotensin system drugs: dual therapy | evidence-context | Advice. 2016 https:\/\/www.nice.org.uk\/advice\/ktt2\/chapter\/evidence-context."},{"key":"BFhr201765_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03256590","volume":"9","author":"MH Crawford","year":"2009","unstructured":"Crawford MH . Combination therapy as first-line treatment for hypertension. Am J Cardiovasc Drugs 2009; 9: 1\u20136.","journal-title":"Am J Cardiovasc Drugs"},{"key":"BFhr201765_CR14","first-page":"171","volume":"3","author":"M Macia-Heras","year":"2012","unstructured":"Macia-Heras M, Del Castillo-Rodriguez N, Navarro Gonz\u00e1lez JF . The Renin-Angiotensin-Aldosterone System in Renal and Cardiovascular Disease and the Effects of its Pharmacological Blockade. J Diabetes Metab 2012; 3: 171.","journal-title":"J Diabetes Metab"},{"key":"BFhr201765_CR15","first-page":"461","volume":"66","author":"DP Bicket","year":"2002","unstructured":"Bicket DP . Using ACE inhibitors appropriately. Am Fam Physician 2002; 66: 461\u2013468.","journal-title":"Am Fam Physician"},{"key":"BFhr201765_CR16","first-page":"178","volume":"107","author":"SG Vijan","year":"2009","unstructured":"Vijan SG . Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. J Indian Med Assoc 2009; 107: 178\u2013182.","journal-title":"J Indian Med Assoc"},{"key":"BFhr201765_CR17","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJM198606263142602","volume":"314","author":"SH Croog","year":"1986","unstructured":"Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH . The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657\u20131664.","journal-title":"N Engl J Med"},{"key":"BFhr201765_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","volume":"95","author":"B Hornig","year":"1997","unstructured":"Hornig B, Kohler C, Drexler H . Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115\u20131118.","journal-title":"Circulation"},{"key":"BFhr201765_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00259-001-0707-z","volume":"29","author":"G Karanikas","year":"2002","unstructured":"Karanikas G, Becherer A, Wiesner K, Dudczak R, Kletter K . ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis. Eur J Nucl Med Mol Imaging 2002; 29: 312\u2013318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BFhr201765_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1161\/01.HYP.33.6.1399","volume":"33","author":"M Ihara","year":"1999","unstructured":"Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, Ideishi M, Arakawa K . Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399\u20131405.","journal-title":"Hypertension"},{"key":"BFhr201765_CR21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1172\/JCI39345","volume":"120","author":"C-C Wei","year":"2010","unstructured":"Wei C-C, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell\u2019italia LJ, Husain A . Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 2010; 120: 1229\u20131239.","journal-title":"J Clin Invest"},{"key":"BFhr201765_CR22","first-page":"15","volume":"3","author":"T Fulmer","year":"2010","unstructured":"Fulmer T . ACE in the hole. SciBX Sci-Bus Exch 2010; 3: 15.","journal-title":"SciBX Sci-Bus Exch"},{"key":"BFhr201765_CR23","doi-asserted-by":"publisher","first-page":"F37","DOI":"10.1152\/ajprenal.00519.2009","volume":"298","author":"S Park","year":"2010","unstructured":"Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, Harrison-Bernard LM . Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol 2010; 298: F37\u2013F48.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFhr201765_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/jhh.2009.34","volume":"24","author":"J Blacher","year":"2010","unstructured":"Blacher J, Evans A, Arveiler D, Amouyel P, Ferri\u00e8res J, Bingham A, Yarnell J, Haas B, Montaye M, Ruidavets J-B, Ducimeti\u00e8re P . PRIME Study Group. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens 2010; 24: 19\u201326.","journal-title":"J Hum Hypertens"},{"key":"BFhr201765_CR25","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/ndt\/gfx166.MP248","volume":"32","author":"JI Shen","year":"2017","unstructured":"Shen JI, Saxena AB, Montez-Rath ME, Chang TI, Winkelmayer WC . Angiotensin converting enzyme inhibitor\/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis. Nephrol Dial Transplant 2017; 32: 862\u2013869.","journal-title":"Nephrol Dial Transplant"},{"key":"BFhr201765_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-88-470-2601-8_24","volume-title":"Special Issues in Hypertension","author":"Alberto Zanchetti","year":"2012","unstructured":"Zanchetti A. Residual Risk in Treated Hypertension. In: Adel EB, Giuseppe M (eds), Special Issues in Hypertension, 2012; pp 309\u2013321."},{"key":"BFhr201765_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1253\/circj.CJ-13-1494","volume":"78","author":"H-Y Lee","year":"2014","unstructured":"Lee H-Y, Sakuma I, Ihm S-H, Goh C-W, Koh KK . Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 2014; 78: 281\u2013287.","journal-title":"Circ J"},{"key":"BFhr201765_CR28","first-page":"123","volume":"16","author":"A Barreras","year":"2003","unstructured":"Barreras A, Gurk-Turner C . Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003; 16: 123\u2013126.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"BFhr201765_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.7326\/0003-4819-141-9-200411020-00011","volume":"141","author":"VC Lee","year":"2004","unstructured":"Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR . Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693\u2013704.","journal-title":"Ann Intern Med"},{"key":"BFhr201765_CR30","first-page":"773","volume":"57","author":"A Grothusen","year":"2009","unstructured":"Grothusen A, Divchev D, Luchtefeld M, Schieffer B . Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Minerva Cardioangiol 2009; 57: 773\u2013785.","journal-title":"Minerva Cardioangiol"},{"key":"BFhr201765_CR31","doi-asserted-by":"publisher","first-page":"e9946","DOI":"10.1371\/journal.pone.0009946","volume":"5","author":"A Kuenzli","year":"2010","unstructured":"Kuenzli A, Bucher HC, Anand I, Arutiunov G, Kum LC, McKelvie R, Afzal R, White M, Nordmann AJ . Meta-analysis of combined therapy with angiotensin receptor antagonists vs. ACE inhibitors alone in patients with heart failure. PLoS ONE 2010; 5: e9946.","journal-title":"PLoS ONE"},{"key":"BFhr201765_CR32","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","volume":"385","author":"SC Palmer","year":"2015","unstructured":"Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GFM . Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015; 385: 2047\u20132056.","journal-title":"Lancet"},{"key":"BFhr201765_CR33","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, K\u00f8ber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM . Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893\u20131906.","journal-title":"N Engl J Med"},{"key":"BFhr201765_CR34","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","volume":"167","author":"CO Phillips","year":"2007","unstructured":"Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM . Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930\u20131936.","journal-title":"Arch Intern Med"},{"key":"BFhr201765_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","volume":"14","author":"R Lakhdar","year":"2008","unstructured":"Lakhdar R, Al-Mallah MH, Lanfear DE . Safety and tolerability of angiotensin-converting enzyme inhibitor vs. the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008; 14: 181\u2013188.","journal-title":"J Card Fail"},{"key":"BFhr201765_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JFE Mann","year":"2008","unstructured":"Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Mets\u00e4rinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S . ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547\u2013553.","journal-title":"Lancet"},{"key":"BFhr201765_CR37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"ONTARGET Investigators ONTARGET Investigators Yusuf S . ONTARGET Investigators Teo KK . ONTARGET Investigators Pogue J . ONTARGET Investigators Dyal L . ONTARGET Investigators Copland I . ONTARGET Investigators Schumacher H . ONTARGET Investigators Dagenais G . ONTARGET Investigators Sleight P . ONTARGET Investigators Anderson C . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547\u20131559.","journal-title":"N Engl J Med"},{"key":"BFhr201765_CR38","doi-asserted-by":"publisher","first-page":"f360","DOI":"10.1136\/bmj.f360","volume":"346","author":"H Makani","year":"2013","unstructured":"Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH . Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013; 346: f360.","journal-title":"BMJ"},{"key":"BFhr201765_CR39","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","volume":"123","author":"SW Tobe","year":"2011","unstructured":"Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JFE . ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123: 1098\u20131107.","journal-title":"Circulation"},{"key":"BFhr201765_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3317\/jraas.2000.002","volume":"1","author":"P Sleight","year":"2000","unstructured":"Sleight P . The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1: 18\u201320.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFhr201765_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","author":"S Yusuf","year":"2008","unstructured":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Yusuf S . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Teo K . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Anderson C . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Pogue J . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Dyal L . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Copland I . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Schumacher H . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Dagenais G . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Sleight P . Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174\u20131183.","journal-title":"Lancet"},{"key":"BFhr201765_CR42","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1681\/ASN.2006050445","volume":"18","author":"WBA Eijkelkamp","year":"2007","unstructured":"Eijkelkamp WBA, Zhang Z, Remuzzi G, Parving H-H, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D . Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540\u20131546.","journal-title":"J Am Soc Nephrol"},{"key":"BFhr201765_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.amjmed.2007.11.016","volume":"121","author":"MM Shafiq","year":"2008","unstructured":"Shafiq MM, Menon DV, Victor RG . Oral direct renin inhibition: premise, promise, and potential limitations of a new class of antihypertensive drug. Am J Med 2008; 121: 265\u2013271.","journal-title":"Am J Med"},{"key":"BFhr201765_CR44","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","volume":"114","author":"MH Strauss","year":"2006","unstructured":"Strauss MH, Hall AS . Angiotensin receptor blockers may increase risk of myocardial infarction. Circulation 2006; 114: 838\u2013854.","journal-title":"Circulation"},{"key":"BFhr201765_CR45","doi-asserted-by":"publisher","first-page":"e1001971","DOI":"10.1371\/journal.pmed.1001971","volume":"13","author":"F Catal\u00e1-L\u00f3pez","year":"2016","unstructured":"Catal\u00e1-L\u00f3pez F, Mac\u00edas Saint-Gerons D, Gonz\u00e1lez-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tob\u00edas A, de la Fuente-Honrubia C, Tabar\u00e9s-Seisdedos R, Hutton B . Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med 2016; 13: e1001971.","journal-title":"PLoS Med"},{"key":"BFhr201765_CR46","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/2040622313495288","volume":"4","author":"S \u015een","year":"2013","unstructured":"\u015een S, Sab\u0131rl\u0131 S, \u00d6zyi\u011fit T, \u00dcresin Y . Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. Ther Adv Chronic Dis 2013; 4: 232\u2013241.","journal-title":"Ther Adv Chronic Dis"},{"key":"BFhr201765_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/2042018813490779","volume":"4","author":"G Riccioni","year":"2013","unstructured":"Riccioni G . The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient. Ther Adv Endocrinol Metab 2013; 4: 139\u2013145.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"BFhr201765_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","volume":"20","author":"JL Pool","year":"2007","unstructured":"Pool JL, Schmieder RE, Azizi M, Aldigier J-C, Januszewicz A, Zidek W, Chiang Y, Satlin A . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11\u201320.","journal-title":"Am J Hypertens"},{"key":"BFhr201765_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","volume":"25","author":"A Villamil","year":"2007","unstructured":"Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217\u2013226.","journal-title":"J Hypertens"},{"key":"BFhr201765_CR50","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","volume":"49","author":"E O\u2019Brien","year":"2007","unstructured":"O\u2019Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A . Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276\u2013284.","journal-title":"Hypertension"},{"key":"BFhr201765_CR51","doi-asserted-by":"publisher","first-page":"E241","DOI":"10.1136\/heartjnl-2012-302920a.52","volume":"98","author":"R Yan","year":"2012","unstructured":"Yan R, He L, Zhang M, Shan H, Lin L, Wei J . Direct renin inhibitor\u2013aliskiren: a meta-analysis of randomised controlled trials in chronic heart failure patients. Heart 2012; 98: E241\u2013E241.","journal-title":"Heart"},{"key":"BFhr201765_CR52","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/10641963.2016.1200064","volume":"38","author":"K Uneda","year":"2016","unstructured":"Uneda K, Tamura K, Wakui H, Azushima K, Haku S, Kobayashi R, Ohki K, Haruhara K, Kinguchi S, Ohsawa M, Fujikawa T, Umemura S . Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease. Clin Exp Hypertens 2016; 38: 738\u2013743.","journal-title":"Clin Exp Hypertens"},{"key":"BFhr201765_CR53","first-page":"1963","volume":"9","author":"J-T Zhang","year":"2015","unstructured":"Zhang J-T, Chen K-P, Guan T, Zhang S . Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2015; 9: 1963\u20131971.","journal-title":"Drug Des Devel Ther"},{"key":"BFhr201765_CR54","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"H-H Parving","year":"2012","unstructured":"Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA . ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204\u20132213.","journal-title":"N Engl J Med"},{"key":"BFhr201765_CR55","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","volume":"374","author":"JJV McMurray","year":"2016","unstructured":"McMurray JJV, Krum H, Abraham WT, Dickstein K, K\u00f8ber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM . ATMOSPHERE Committees Investigators. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 2016; 374: 1521\u20131532.","journal-title":"N Engl J Med"},{"key":"BFhr201765_CR56","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/hr.2016.61","volume":"39","author":"V Mengal","year":"2016","unstructured":"Mengal V, Silva PH, Tiradentes RV, Santuzzi CH, de Almeida SA, Sena GC, Bissoli NS, Abreu GR, Gouvea SA . Aliskiren and l-arginine treatments restore depressed baroreflex sensitivity and decrease oxidative stress in renovascular hypertension rats. Hypertens Res 2016; 39: 769\u2013776.","journal-title":"Hypertens Res"},{"key":"BFhr201765_CR57","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1681\/ASN.2006010029","volume":"17","author":"A Ichihara","year":"2006","unstructured":"Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, AHMN Nabi, Nishiyama A, Sugaya T, Hayashi M, Inagami T . Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950\u20131961.","journal-title":"J Am Soc Nephrol"},{"key":"BFhr201765_CR58","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/01.HYP.0000215838.48170.0b","volume":"47","author":"A Ichihara","year":"2006","unstructured":"Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M . Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894\u2013900.","journal-title":"Hypertension"},{"key":"BFhr201765_CR59","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1136\/bmj.e42","volume":"344","author":"Z Harel","year":"2012","unstructured":"Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS . The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012; 344: e42.","journal-title":"BMJ"},{"key":"BFhr201765_CR60","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1001\/jama.2013.1954","volume":"309","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, B\u00f6hm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP . Coordinators for the AI and effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125\u20131135.","journal-title":"JAMA"},{"key":"BFhr201765_CR61","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1161\/HYPERTENSIONAHA.112.197046","volume":"60","author":"D Henrion","year":"2012","unstructured":"Henrion D . Why do we need a selective angiotensin II type 2 receptor agonist? Hypertension 2012; 60: 616\u2013617.","journal-title":"Hypertension"},{"key":"BFhr201765_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/hr.2014.132","volume":"38","author":"I Dhande","year":"2015","unstructured":"Dhande I, Ma W, Hussain T . Angiotensin AT2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production. Hypertens Res 2015; 38: 21\u201329.","journal-title":"Hypertens Res"},{"key":"BFhr201765_CR63","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/HYPERTENSIONAHA.115.05204","volume":"65","author":"C Koulis","year":"2015","unstructured":"Koulis C, Chow BSM, McKelvey M, Steckelings UM, Unger T, Thallas-Bonke V, Thomas MC, Cooper ME, Jandeleit-Dahm KA, Allen TJ . AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. Hypertension 2015; 65: 1073\u20131081.","journal-title":"Hypertension"},{"key":"BFhr201765_CR64","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2147\/VHRM.S1905","volume":"4","author":"A Ribeiro-Oliveira","year":"2008","unstructured":"Ribeiro-Oliveira A, Nogueira AI, Pereira RM, Boas WWV, dos Santos RAS, e Silva ACS . The renin\u2013angiotensin system and diabetes: an update. Vasc Health Risk Manag 2008; 4: 787\u2013803.","journal-title":"Vasc Health Risk Manag"},{"key":"BFhr201765_CR65","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1042\/CS20130400","volume":"126","author":"CM Ferrario","year":"2014","unstructured":"Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, Dell\u2019italia LJ . An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci (Lond) 2014; 126: 461\u2013469.","journal-title":"Clin Sci (Lond)"},{"key":"BFhr201765_CR66","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bph.12159","volume":"169","author":"AC Sim\u00f5es e Silva","year":"2013","unstructured":"Sim\u00f5es e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM . ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013; 169: 477\u2013492.","journal-title":"Br J Pharmacol"},{"key":"BFhr201765_CR67","first-page":"181","volume":"61","author":"J Toton-Zuranska","year":"2010","unstructured":"Toton-Zuranska J, Gajda M, Pyka-Fosciak G, Kus K, Pawlowska M, Niepsuj A, Wolkow P, Olszanecki R, Jawien J, Korbut R . AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2010; 61: 181\u2013183.","journal-title":"J Physiol Pharmacol"},{"key":"BFhr201765_CR68","first-page":"77","volume":"63","author":"J Jawien","year":"2012","unstructured":"Jawien J, Toton-Zuranska J, Gajda M, Niepsuj A, Gebska A, Kus K, Suski M, Pyka-Fosciak G, Nowak B, Guzik TJ, Marcinkiewicz J, Olszanecki R, Korbut R . Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol 2012; 63: 77\u201385.","journal-title":"J Physiol Pharmacol"},{"key":"BFhr201765_CR69","doi-asserted-by":"publisher","first-page":"BR389","DOI":"10.12659\/MSM.883478","volume":"18","author":"J Jawien","year":"2012","unstructured":"Jawien J, Toton-Zuranska J, Kus K, Pawlowska M, Olszanecki R, Korbut R . The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis. Med Sci Monit 2012; 18: BR389\u2013BR393.","journal-title":"Med Sci Monit"},{"key":"BFhr201765_CR70","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.atherosclerosis.2015.02.055","volume":"240","author":"J Yang","year":"2015","unstructured":"Yang J, Sun Y, Dong M, Yang X, Meng X, Niu R, Guan J, Zhang Y, Zhang C . Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice. Atherosclerosis 2015; 240: 544\u2013549.","journal-title":"Atherosclerosis"},{"key":"BFhr201765_CR71","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/01.HYP.34.2.296","volume":"34","author":"AJ Roks","year":"1999","unstructured":"Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH . Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999; 34: 296\u2013301.","journal-title":"Hypertension"},{"key":"BFhr201765_CR72","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2174\/138955706776876203","volume":"6","author":"AC Sim\u00f5es e Silva","year":"2006","unstructured":"Sim\u00f5es e Silva AC, Pinheiro SVB, Pereira RM, Ferreira AJ, Santos RAS . The therapeutic potential of Angiotensin-(1-7) as a novel Renin-Angiotensin System mediator. Mini Rev Med Chem 2006; 6: 603\u2013609.","journal-title":"Mini Rev Med Chem"},{"key":"BFhr201765_CR73","doi-asserted-by":"publisher","first-page":"H1560","DOI":"10.1152\/ajpheart.00941.2004","volume":"289","author":"EA Tallant","year":"2005","unstructured":"Tallant EA, Ferrario CM, Gallagher PE . Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005; 289: H1560\u2013H1566.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFhr201765_CR74","first-page":"317","volume":"64","author":"R Olszanecki","year":"2013","unstructured":"Olszanecki R, Suski M, Gebska A, Toton-Zuranska J, Kus K, Madej J, Bujak-Gizycka B, Jawien J, Korbut R . The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin I metabolism in aorta of apoE-knockout mice. J Physiol Pharmacol 2013; 64: 317\u2013320.","journal-title":"J Physiol Pharmacol"},{"key":"BFhr201765_CR75","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S . A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1\u2013E9.","journal-title":"Circ Res"},{"key":"BFhr201765_CR76","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1470320313498631","volume":"15","author":"A Mogielnicki","year":"2014","unstructured":"Mogielnicki A, Kramkowski K, Hermanowicz JM, Leszczynska A, Przyborowski K, Buczko W . Angiotensin-(1-9) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis. J Renin Angiotensin Aldosterone Syst 2014; 15: 13\u201321.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFhr201765_CR77","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/01.ATV.0000253889.09765.5f","volume":"27","author":"V Jankowski","year":"2007","unstructured":"Jankowski V, Vanholder R, van der Giet M, T\u00f6lle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TNA, Tepel M, Schuchardt M, Schl\u00fcter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J . Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007; 27: 297\u2013302.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFhr201765_CR78","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.110.161836","volume":"57","author":"R Yang","year":"2011","unstructured":"Yang R, Smolders I, Vanderheyden P, Demaegdt H, Van Eeckhaut A, Vauquelin G, Lukaszuk A, Tourw\u00e9 D, Chai SY, Albiston AL, Nahmias C, Walther T, Dupont AG . Pressor and renal hemodynamic effects of the novel angiotensin A peptide are angiotensin II type 1A receptor dependent. Hypertension 2011; 57: 956\u2013964.","journal-title":"Hypertension"},{"key":"BFhr201765_CR79","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","volume":"112","author":"RQ Lautner","year":"2013","unstructured":"Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, Soares E, Barbosa C, Kjeldsen F, Oliveira A, Braga J, Savergnini S, Maia G, Peluso AB, Passos-Silva D, Ferreira A, Alves F, Martins A, Raizada M, Paula R, Motta-Santos D, Klempin F, Kemplin F, Pimenta A, Alenina N, Sinisterra R, Bader M, Campagnole-Santos MJ, Santos RAS . Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 2013; 112: 1104\u20131111.","journal-title":"Circ Res"},{"key":"BFhr201765_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1023\/A:1011198432013","volume":"15","author":"MA Pfeffer","year":"2001","unstructured":"Pfeffer MA . New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 11\u201313.","journal-title":"Cardiovasc Drugs Ther"},{"key":"BFhr201765_CR81","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","volume":"41","author":"S Keidar","year":"2003","unstructured":"Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M . Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003; 41: 955\u2013963.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFhr201765_CR82","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jsbmb.2004.12.010","volume":"93","author":"JW Funder","year":"2005","unstructured":"Funder JW . RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005; 93: 121\u2013125.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFhr201765_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B . EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11\u201321.","journal-title":"N Engl J Med"},{"key":"BFhr201765_CR84","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/hr.2015.19","volume":"38","author":"A Sato","year":"2015","unstructured":"Sato A . The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hypertens Res 2015; 38: 367\u2013374.","journal-title":"Hypertens Res"},{"key":"BFhr201765_CR85","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.jacc.2011.04.049","volume":"58","author":"P Rossignol","year":"2011","unstructured":"Rossignol P, M\u00e9nard J, Fay R, Gustafsson F, Pitt B, Zannad F . Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol 2011; 58: 1958\u20131966.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr201765_CR86","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1210\/jc.2003-032149","volume":"89","author":"DG Levy","year":"2004","unstructured":"Levy DG, Rocha R, Funder JW . Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736\u20132740.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFhr201765_CR87","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2215\/CJN.09421209","volume":"5","author":"A Vukusich","year":"2010","unstructured":"Vukusich A, Kunstmann S, Varela C, Gainza D, Bravo S, Sepulveda D, Cavada G, Michea L, Marusic ET . A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1380\u20131387.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFhr201765_CR88","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/hr.2014.171","volume":"38","author":"G Mul\u00e8","year":"2015","unstructured":"Mul\u00e8 G, Nardi E, Guarino L, Cacciatore V, Geraci G, Calcaterra I, Oddo B, Vaccaro F, Cottone S . Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease. Hypertens Res 2015; 38: 276\u2013283.","journal-title":"Hypertens Res"},{"key":"BFhr201765_CR89","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/hr.2015.34","volume":"38","author":"C Cuspidi","year":"2015","unstructured":"Cuspidi C, Tadic M, Sala C . Aldosterone and abnormal left ventricular geometry in chronic kidney disease. Hypertens Res 2015; 38: 314\u2013316.","journal-title":"Hypertens Res"},{"key":"BFhr201765_CR90","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","volume":"96","author":"IZ Jaffe","year":"2005","unstructured":"Jaffe IZ, Mendelsohn ME . Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643\u2013650.","journal-title":"Circ Res"},{"key":"BFhr201765_CR91","doi-asserted-by":"publisher","first-page":"10035","DOI":"10.1038\/srep10035","volume":"5","author":"A Nehme","year":"2015","unstructured":"Nehme A, Cerutti C, Dhaouadi N, Gustin MP, Courand P-Y, Zibara K, Bricca G . Atlas of tissue renin-angiotensin-aldosterone system in human: a transcriptomic meta-analysis. Sci Rep 2015; 5: 10035.","journal-title":"Sci Rep"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/hr201765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/hr201765","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/hr.2017.65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/hr201765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T06:04:41Z","timestamp":1650175481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr201765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFhr201765"],"URL":"https:\/\/doi.org\/10.1038\/hr.2017.65","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"assertion":[{"value":"8 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}